The efficacy and safety of chemotherapy with or without anti‐PD‐1 for the first‐line treatment of advanced urothelial carcinoma
Abstract Objective To compare the efficacy and safety of first‐line anti‐PD‐1 combined with chemotherapy versus chemotherapy alone in patients with advanced urothelial carcinoma (UC). Method Patients with advanced UC who received first‐line treatment of chemotherapy (n = 51, gemcitabine/paclitaxel [...
Main Authors: | Fuxin Han, Zhaozhen Wu, Jiaxin Chen, Meicen Liu, Yi Hu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-12-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.6671 |
Similar Items
-
Efficacy and Adverse Reaction of Tislelizumab Combined with Chemotherapy on Urothelial Carcinoma
by: WEI Zongjie, et al.
Published: (2022-07-01) -
The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy
by: Jiwei Huang, et al.
Published: (2022-12-01) -
Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancer
by: Xue Huang, et al.
Published: (2023-11-01) -
Neoadjuvant chemotherapy improves survival rate in advanced urothelial carcinoma
by: Chia-Chun Tsai, et al.
Published: (2013-04-01) -
Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)